Navigation Links
NICE Setback Rules for Pfizer's Inhaled Insulin

Diabetics with needle phobia and patients with severe problems in injection sites get benefited from Pfizer’s Exubera, an inhaled insulin product (short-acting, powder form of insulin) //– said The National Institute for Health and Clinical Excellence (NICE), Britain's watchdog.

A suggestion has already said by the National Institute for Health and Clinical Excellence (NICE) that inhaled insulin are not money worthy.

But now the revised report by the NICE says it can be used with flexibility – said Andrea Sutcliffe, deputy chief executive at NICE.

Both Type 1 and Type 2 diabetics can use Exubera, since it has got marketing licence in Europe and the United States.

A report from NICE (a center dealing with quality and its cost worth of treatments) say it costs more than its clinical use. So a single year per patient needs 1,102 pounds.

NICE have already been set reduced access to Alzheimer's drugs as pointing out on drugmakers and patient groups, now comes the Exubera proposal which has found to be the latest controversial ruling from NICE.

Since then 1920 Exubera only proved to benefit diabetic patients as well as clinicians by cutting on its treatment process and risks of complications – argued Pfizer.


Page: 1

Related medicine news :

1. Acute Shortage Of Dentists in UK: Oral Care for Elders To Suffer A Setback
2. Setback to Medical Strike – AIIMS & MAMC Doctors to Resume Wor
3. Key step forward on International Health Rules
4. U.S. To Tighten Sick Passenger, Quarantine Rules
5. Novel Rules And Regulations For Cardiovascular Catheterization Labs.
6. FDA to Revise Herpes Test Rules in the US
7. Aussie Rules, High on Football Injuries
8. Lady Patient Died after Hospital Turned Inhospitable, Rules Sheriff
9. Aamir Rules Out Apologising For Remarks On Narmada Issue
10. WHO Rules Out Human Transmission Of Bird Flu In 4 Cases
11. Japanese Court Rules In Patients Favour Over Hepatitis C Scandal
Post Your Comments:

(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
(Date:6/25/2016)... ... 25, 2016 , ... First Choice Emergency Room , the largest network ... the Medical Director of its new Mesquite-Samuell Farm facility. , “We are pleased ... location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/25/2016)... ... ... Conventional wisdom preaches the benefits of moderation, whether it’s a matter of ... too high can result in disappointment, perhaps even self-loathing. However, those who set the ... Research from reveals that behind the tendency to set low expectations ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... 24, 2016 The Academy of Managed Care ... that would allow biopharmaceutical companies to more easily ... make formulary and coverage decisions, a move that addresses ... medicines. The recommendations address restrictions in the ... the drug label, a prohibition that hinders decision makers ...
(Date:6/24/2016)... , June 24, 2016 ... Market by Type (Standard Pen Needles, Safety Pen Needles), ... (Insulin, GLP-1, Growth Hormone), Mode of Purchase (Retail, Non-Retail) ... MarketsandMarkets, This report studies the market for the forecast ... to reach USD 2.81 Billion by 2021 from USD ...
Breaking Medicine Technology: